Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
Cervical Cancer|Genital Wart|CIN|VIN|Papillomavirus Infections
BIOLOGICAL: Zerun HPV-9|BIOLOGICAL: GARDASIL ®9
Geometric Mean Titers (GMT) of HPV neutralizing antibodies, HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 neutralizing antibodies GMT, 30 days postdose 3 (Month 7)|Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58, Seroconversion is defined as a participant in PPS who was anti-HPV seronegative at Day 0 (before vaccination) and became seropositive 30days after the third dose (Month 7)., 30 days postdose 3 (Month 7)
Percentage of subjects reporting solicited local symptoms, Solicited local symptoms assessed including pain, redness, swelling, induration and pruritus., 0-7 days after each dose|Percentage of subjects reporting solicited general symptoms, Solicited general symptoms assessed including fever, headache, fatigue, nausea, diarrhea, vomiting, myalgia, allergic reaction, 0-7 days after each dose|Percentage of subjects reporting unsolicited adverse events (AEs), An unsolicited adverse event is defined as any adverse event (AE) reported in addition to those solicited during the clinical study., 0-30 days after each dose|Percentage of subjects reporting serious adverse events (SAEs), Serious adverse events are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject., Month 0 to Month 12
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.